<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01240226</url>
  </required_header>
  <id_info>
    <org_study_id>GDC4931g</org_study_id>
    <nct_id>NCT01240226</nct_id>
  </id_info>
  <brief_title>A Study to Determine the Relative Bioavailability of a Tablet Formulation of GDC-0941 and the Effect of Ketoconazole on the Pharmacokinetics of the GDC-0941 Tablet</brief_title>
  <official_title>An Open-Label, 2-Part Study to Determine the Relative Bioavailability of a Tablet Formulation of GDC-0941 and the Effect of Ketoconazole on the Pharmacokinetics of the GDC-0941 Tablet</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Genentech, Inc.</source>
  <brief_summary>
    <textblock>
      This will be a single-center, open-label, randomized, 2-part study to determine the relative&#xD;
      bioavailability of GDC-0941 capsule and market-image tablet formulations and the effect of&#xD;
      ketoconazole on the pharmacokinetics of the GDC-0941 market-image tablet formulation.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2010</start_date>
  <completion_date type="Actual">December 2010</completion_date>
  <primary_completion_date type="Actual">December 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence, nature, and severity of adverse events</measure>
    <time_frame>Through study completion or early study discontinuation</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic parameters of GDC-0941 (total exposure, maximum and minimum plasma concentration)</measure>
    <time_frame>Prior to and after GDC-0941 dosing</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Healthy Volunteer</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GDC-0941</intervention_name>
    <description>Oral repeating dose</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GDC-0941</intervention_name>
    <description>Oral repeating dose</description>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ketoconazole</intervention_name>
    <description>Oral repeating dose</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          -  Medically healthy as determined by the absence of clinically significant findings in&#xD;
             the physical examination, medical history, vital sign measurements, clinical&#xD;
             laboratory tests, or 12-lead electrocardiograms (ECGs)&#xD;
&#xD;
          -  For female subjects: postmenopausal and without recent history of menorrhea,&#xD;
             surgically sterile or using an effective method of contraception such as oral or&#xD;
             transdermal contraceptives, double-barrier contraception, intrauterine device, depot&#xD;
             progesterone, or implanted contraceptive devices, from Day -1 until 45 days after&#xD;
             study drug completion/discharge; female subjects must have a negative pregnancy test&#xD;
             at Screening and on Day -1&#xD;
&#xD;
          -  For male subjects: sterile or a sterile sexual partner, or agreement to use 2 forms of&#xD;
             medically acceptable methods of contraception, one of which is a barrier, and&#xD;
             agreement not to donate sperm from Screening throughout the study period and for at&#xD;
             least 3 months after the last dose of study drug.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          -  History of clinical manifestations of significant metabolic (including type 1 and 2&#xD;
             diabetes), hepatic, renal, hematological, pulmonary, cardiovascular, endocrine,&#xD;
             gastrointestinal (including gastric or duodenal ulcers), urological, neurological, or&#xD;
             psychiatric disease, or cancer&#xD;
&#xD;
          -  History of inflammatory arthritis&#xD;
&#xD;
          -  History of symptomatic hypotension&#xD;
&#xD;
          -  History of severe physical injury, direct impact trauma, or neurological trauma within&#xD;
             a specified timeframe prior to initiation of study treatment&#xD;
&#xD;
          -  History of seizure disorders&#xD;
&#xD;
          -  History of bipolar or major depressive disorder&#xD;
&#xD;
          -  History of stomach or intestinal surgery or resection (except appendectomy, hernia&#xD;
             repair, and cholecystectomy)&#xD;
&#xD;
          -  History or presence of an abnormal ECG&#xD;
&#xD;
          -  History of ventricular dysrhythmias or risk factors for ventricular dysrhythmias&#xD;
&#xD;
          -  History of alcoholism, drug abuse, or drug addiction&#xD;
&#xD;
          -  Use of any nicotine-containing or nicotine-replacement products within a specified&#xD;
             timeframe prior to initiation of study treatment&#xD;
&#xD;
          -  Use of medications capable of inhibiting hepatic enzymes within a specified timeframe&#xD;
             prior to initiation of study treatment&#xD;
&#xD;
          -  Participation in any other investigational drug study in which receipt of an&#xD;
             investigational study drug occurred within a specified timeframe prior to initiation&#xD;
             of study treatment&#xD;
&#xD;
          -  Use of any prescription medications/products including monoamine oxidase inhibitors,&#xD;
             thioridazine, pimozide, or antidepressants within a specified timeframe prior to&#xD;
             initiation of study treatment (2 weeks for antibiotics) (except hormone-replacement&#xD;
             therapy or 2 weeks use of narcotics for pain)&#xD;
&#xD;
          -  Any vaccination or immunization within a specified timeframe prior to initiation of&#xD;
             study treatment&#xD;
&#xD;
          -  Routine use of PPIs or histamine H2-receptor antagonists, or any use of these drugs&#xD;
             within a specified timeframe prior to initiation of study treatment&#xD;
&#xD;
          -  Known hypersensitivity to ketoconazole or other azole antifungals&#xD;
&#xD;
          -  Use of any over-the-counter, nonprescription preparations (including supplements,&#xD;
             vitamins, minerals, phytotherapeutic/herbal/plant-derived preparations, tryptophans,&#xD;
             and St. John's wort) within a specified timeframe prior to initiation of study&#xD;
             treatment&#xD;
&#xD;
          -  Use of alcohol-containing, grapefruit-containing, or caffeine-containing foods or&#xD;
             beverages within a specified timeframe prior to initiation of study treatment&#xD;
&#xD;
          -  Donated blood within within a specified timeframe prior to initiation of study&#xD;
             treatment&#xD;
&#xD;
          -  Received blood products within a specified timeframe prior to initiation of study&#xD;
             treatment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Scott Holden, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Genentech, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78744</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2012</verification_date>
  <study_first_submitted>November 10, 2010</study_first_submitted>
  <study_first_submitted_qc>November 10, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 15, 2010</study_first_posted>
  <last_update_submitted>March 2, 2017</last_update_submitted>
  <last_update_submitted_qc>March 2, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 3, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ketoconazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

